Pay in 4 interest-free payments of $5.53 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
In contrast, a multicenter retrospective cohort study, including a higher-risk population (23% with CKD) reported slower eGFR decline and lower risks of CKD progression and doubling of serum creatinine among SGLT2 inhibitor users compared with GLP-1 receptor agonist users
Advances in artificial intelligence and machine learning might soon offer predictive insights and individualized recommendations, allowing patients to take a more active role in their health
Impressive results
5 A recent meta-analysis of 764 RCTs including 421,346 people with type 2 diabetes found that both medicine classes reduced: 6 All-cause mortality Cardiovascular mortality Non-fatal myocardial infarction Kidney failure The mechanism by which these medicines reduce adverse cardiovascular outcomes remains uncertain
By addressing the hormonal and metabolic factors underlying weight gain, micro-dosing offers a targeted solution that complements other lifestyle changes
